REYON Pharmaceutical Co., Ltd. (KRX:102460)

Market Cap	200.65B
Revenue (ttm)	148.30B
Net Income (ttm)	4.15B
Shares Out	18.34M
EPS (ttm)	226.00
PE Ratio	48.41
Forward PE	n/a
Dividend	150.00 (1.37%)
Ex-Dividend Date	n/a

Volume	10,846
Average Volume	13,211
Open	11,430
Previous Close	11,350
Day's Range	11,300 - 11,570
52-Week Range	9,830 - 18,650
Beta	0.77
RSI	41.12
Earnings Date	May 14, 2025

About REYON Pharmaceutical

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1955
• Employees: 448
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 102460

Financial Performance

In 2024, REYON Pharmaceutical's revenue was 148.30 billion, a decrease of -1.83% compared to the previous year's 151.07 billion. Earnings were 4.15 billion, an increase of 15.85%.